Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
Author:
Top Cited Papers
- 13 May 2022
- journal article
- research article
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 26 (4) , 467-475
Abstract
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617) is a radioligand therapeutic agent that is being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of prostate-specific membrane antigen (PSMA)-expressing metastatic prostate cancer. The active part of the radiopharmaceutical is lutetium-177, which is linked to a ligand that binds to prostate-specific membrane antigen (PSMA), a transmembrane enzyme overexpressed in primary and metastatic prostate cancers. Based on efficacy results from the phase 3 VISION trial, lutetium Lu 177 vipivotide tetraxetan was approved in the USA on 23 March 2022 for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Regulatory review in the EU and other countries is underway. This article summarizes the milestones in the development of Lutetium Lu 177 vipivotide tetraxetan leading to this first approval as a therapeutic radioligand for mCRPC.Keywords
This publication has 29 references indexed in Scilit:
- Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)European Urology Oncology, 2021
- Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJournal of Nuclear Medicine, 2019
- Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricaciesProstate Cancer and Prostatic Diseases, 2019
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerEuropean Urology, 2019
- Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionClinical Genitourinary Cancer, 2019
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJournal of Nuclear Medicine, 2018
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyThe Lancet Oncology, 2018
- Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imagingNuclear Medicine Communications, 2016
- German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsJournal of Nuclear Medicine, 2016
- Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinomaCancer, 1998